MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Intersect ENT lures Hologic’s West for CEO | Personnel Moves, June 28, 2019

Intersect ENT lures Hologic’s West for CEO | Personnel Moves, June 28, 2019

By

Intersect ENT names Tom West CEOIntersect ENT (NSDQ:XENT) yesterday named Hologic (NSDQ:HOLX) executive Tom West to be its new president & CEO effective July 22.

West, who has been president of Hologic’s diagnostics solutions division since October 2014, is a Johnson & Johnson (NYSE:JNJ) veteran, Menlo Park, Calif.-based Intersect ENT said. The company in May tapped lead director Kieran Gallahue to be interim CEO after Lisa Earnhardt stepped away to become head of medical devices for Abbott (NYSE:ABT).

“Tom is a proven healthcare leader bringing more than two decades of medical technology experience to Intersect ENT. We look forward to leveraging his deep knowledge of and expertise in accelerating growth through commercial execution, product innovation and the building of strong, integrated teams,” Gallahue said in prepared remarks. “The board and I are impressed with Tom’s strategic insights and established track record of strong execution and successful product commercialization. We believe Tom’s leadership will be a great benefit to us as we continue to advance our products in the marketplace, drive growth across our portfolio and deliver on our goal of making localized drug delivery the standard of care for patients suffering from chronic sinusitis.”

“I’m thrilled to join Intersect ENT at this time and look forward to building on the company’s history of innovation to drive accelerated growth via strong execution and with consistent financial and operational performance,” West added. “I am excited to join the Intersect ENT team in our mission of transforming care in the ear, nose & throat specialty and extend the company’s leadership in innovation in localized drug delivery. With focused execution across both Intersect ENT’s commercialized products and pipeline of innovative, clinically meaningful therapies, I am confident that we can build an even stronger foundation for future growth as we enhance value to our shareholders.”

Intersect ENT also said that it’s begun a search to replace CFO Jeri Hilleman, who’s is slated to step down at the beginning of next year to focus on “board responsibilities.”

“We want to express our deep appreciation for Jeri’s many and significant accomplishments over the years, and are deeply grateful for her commitment to ensure a seamless transition throughout this planned process,” Gallahue said. “Jeri has contributed broadly to the organization over the years, and we wish her well in the next stage of her career.”

 Globus Medical taps Pfeil as new CFO
Globus Medical (NYSE:GMED) yesterday tapped Keith Pfeil, the finance chief for consumer products company CSS Industries, to be its new CFO effective August 19.

Wayne, Pa.-based Globus promoted CFO Dan Scavilla to chief commercial officer last August, saying he’d keep the finance chief role until a replacement was found.

“We are delighted to have Keith join our senior team. He’s an accomplished executive with strong track record of sound financial leadership, bringing efficiency to operations and corporate value creation,” president & CEO Dave Demski said in prepared remarks. “We believe Keith will be a valuable addition to our executive management team and will help support our growth as Globus Medical becomes a larger player in the musculoskeletal market.”
Read more

 Apollo Endosurgery founder McWilliams joins Santé Ventures
VC shop Santé Ventures said it named Dennis McWilliams, the former founder, CEO and CCO at Apollo Endosurgery (NSDQ:APEN), as a venture partner.

“Dennis has a proven track record for bringing creativity, energy and intellect to the process of building new ventures in life sciences,” Santé co-founder & managing director Kevin Lalande said in prepared remarks. “We welcome Dennis to the team and in addition to benefitting from his experience and insights, we are confident he can help us leverage our deep network of relationships in identifying and expanding opportunities within our investment focus. Dennis will fit well into our collaborative culture and we are excited to partner with him to advance new products and services to better serve patients.”
Read more

 Pfizer grabs ex-FDA chief Gottlieb for board
Pfizer (NYSE:PFE) named former FDA commissioner Dr. Scott Gottlieb to its board of directors.

“We welcome Dr. Gottlieb to Pfizer’s board of directors,” CEO Albert Bourla said in prepared remarks. “Through his work as a physician and his time at the FDA, Scott has continually demonstrated an understanding of both patients’ needs and the rapidly changing dynamics of biopharmaceutical research and development.”

“Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives,” added chairman Ian Read.
Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]